Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yu Miura
Observed names:
Y. Miura,
YU MIURA
Institutions:
Saitama International Medical Center,
Saitama Medical University
Observed institutions:
Saitama International Medical Center,
Gunma Prefectural Cancer Center,
Saitama Medical Center, Saitama Medical University,
Saitama Medical University
ORCID:
0000-0002-2752-5873
Observed ORCID:
0000-0002-2752-5873
OpenAlex ID:
A5078969338
CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy
2019
·
Hiroshi Kagamu
, Shigehisa Kitano
, et al.
·
Cancer Immunology Research
·
278
Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients
2019
·
Ayako Shiono
, Kyoichi Kaira
, et al.
·
Thoracic Cancer
·
76
PDF
Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer
2020
·
Kosuke Hashimoto
, Kyoichi Kaira
, et al.
·
Journal of Clinical Medicine
·
62
PDF
Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events
2020
·
Yu Miura
, Atsuto Mouri
, et al.
·
Thoracic Cancer
·
60
PDF
Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab
2019
·
Ou Yamaguchi
, Kyoichi Kaira
, et al.
·
Thoracic Cancer
·
56
PDF
Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer
2019
·
Atsuto Mouri
, Kyoichi Kaira
, et al.
·
Cancer Chemotherapy and Pharmacology
·
52
Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy
2022
·
Hiroshi Kagamu
, Satoshi Yamasaki
, et al.
·
Cancer Research
·
47
PDF
Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%
2020
·
Ou Yamaguchi
, Kyoichi Kaira
, et al.
·
Scientific Reports
·
38
PDF
Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer
2020
·
Satoshi Saito
, Takanori Abe
, et al.
·
Clinical and Translational Radiation Oncology
·
37
PDF
Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non‐small cell lung cancer harboring EGFR mutation
2020
·
Ou Yamaguchi
, Kyoichi Kaira
, et al.
·
Thoracic Cancer
·
36
PDF
Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer
2019
·
Takahiro Uchida
, Kyoichi Kaira
, et al.
·
Thoracic Cancer
·
34
PDF
Pre‐existing interstitial lung disease does not affect prognosis in non‐small cell lung cancer patients with PD‐L1 expression ≥50% on first‐line pembrolizumab
2020
·
Ou Yamaguchi
, Kyoichi Kaira
, et al.
·
Thoracic Cancer
·
28
PDF
Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer
2023
·
Kyoichi Kaira
, Ou Yamaguchi
, et al.
·
Discover Oncology
·
26
PDF
Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer in comparison with chemoradiotherapy alone
2020
·
Takanori Abe
, Satoshi Saito
, et al.
·
Thoracic Cancer
·
26
PDF
Clinical Utility of Inflammatory and Nutritious Index as Therapeutic Prediction of Nivolumab plus Ipilimumab in Advanced Non-Small Cell Lung Cancer
2023
·
Ou Yamaguchi
, Kyoichi Kaira
, et al.
·
Oncology
·
24
PDF
Effect of Systemic Steroid Use for Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Receiving PD-1 Blockade Drugs
2021
·
Atsuto Mouri
, Kyoichi Kaira
, et al.
·
Journal of Clinical Medicine
·
22
PDF
Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation
2019
·
Ou Yamaguchi
, Kyoichi Kaira
, et al.
·
Cancer Chemotherapy and Pharmacology
·
20
Effectiveness of EGFR‐TKI rechallenge immediately after PD ‐1 blockade failure
2021
·
Kyoichi Kaira
, Kunihiko Kobayashi
, et al.
·
Thoracic Cancer
·
18
Prognostic factors of liver metastases in extensive-stage small cell lung cancer receiving chemo-immunotherapy
2025
·
Kyoichi Kaira
, Yuhei Kurata
, et al.
·
Translational Lung Cancer Research
·
16
Prospective assessment using 18F-FDG PET/CT as a novel predictor for early response to PD-1 blockade in non-small-cell lung cancer
2022
·
Ou Yamaguchi
, Kyoichi Kaira
, et al.
·
Scientific Reports
·
16
PDF
Clinical impact of inflammatory and nutrition index based on metabolic tumor activity in non‑small cell lung cancer treated with immunotherapy
2024
·
Koki Ito
, Kousuke Hashimoto
, et al.
·
Oncology Letters
·
14
PDF
Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers
2021
·
Atsuto Mouri
, Kyoichi Kaira
, et al.
·
Frontiers in Oncology
·
14
PDF
Feasibility of intensity modulated radiotherapy with involved field radiotherapy for Japanese patients with locally advanced non-small cell lung cancer
2021
·
Takanori Abe
, Misaki Iino
, et al.
·
Journal of Radiation Research
·
13
PDF
Prognostic Potential of Metabolic Activity on 18F-FDG Accumulation in Advanced NSCLC Receiving Combining Chemotherapy Plus PD-1 Blockade
2022
·
Kosuke Hashimoto
, Kyoichi Kaira
, et al.
·
Journal of Immunotherapy
·
12
Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non‐small cell lung cancer
2022
·
Hisao Imai
, Erika Naito
, et al.
·
Thoracic Cancer
·
12
Show more works
View as search
Works count:
78
Citation count:
1,149
H-index:
18
I10-index:
26
Year
Topic
Type